Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

307 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets.
Monks A, Scudiero DA, Johnson GS, Paull KD, Sausville EA. Monks A, et al. Anticancer Drug Des. 1997 Oct;12(7):533-41. Anticancer Drug Des. 1997. PMID: 9365500 Review. No abstract available.
Target selection issues in drug discovery and development.
Sausville EA. Sausville EA. J Chemother. 2004 Nov;16 Suppl 4:16-8. doi: 10.1179/joc.2004.16.Supplement-1.16. J Chemother. 2004. PMID: 15688602 Review.
FR901228 causes mitotic arrest but does not alter microtubule polymerization.
Sandor V, Robbins AR, Robey R, Myers T, Sausville E, Bates SE, Sackett DL. Sandor V, et al. Anticancer Drugs. 2000 Jul;11(6):445-54. doi: 10.1097/00001813-200007000-00005. Anticancer Drugs. 2000. PMID: 11001385
SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, Pedley RB, Kelland LR, Alley MC, Schultz R, Hollingshead MG, Schweikart KM, Tomaszewski JE, Sausville EA, Gregson SJ, Howard PW, Thurston DE. Hartley JA, et al. Cancer Res. 2004 Sep 15;64(18):6693-9. doi: 10.1158/0008-5472.CAN-03-2941. Cancer Res. 2004. PMID: 15374986
Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data.
Wallqvist A, Rabow AA, Shoemaker RH, Sausville EA, Covell DG. Wallqvist A, et al. Bioinformatics. 2003 Nov 22;19(17):2212-24. doi: 10.1093/bioinformatics/btg302. Bioinformatics. 2003. PMID: 14630650
Application of high-throughput, molecular-targeted screening to anticancer drug discovery.
Shoemaker RH, Scudiero DA, Melillo G, Currens MJ, Monks AP, Rabow AA, Covell DG, Sausville EA. Shoemaker RH, et al. Curr Top Med Chem. 2002 Mar;2(3):229-46. doi: 10.2174/1568026023394317. Curr Top Med Chem. 2002. PMID: 11944818 Review.
Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines.
Wallqvist A, Connelly J, Sausville EA, Covell DG, Monks A. Wallqvist A, et al. Mol Pharmacol. 2006 Mar;69(3):737-48. doi: 10.1124/mol.105.017061. Epub 2005 Dec 6. Mol Pharmacol. 2006. PMID: 16332985
In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative.
Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH, Sausville EA. Hollingshead M, et al. Cancer Chemother Pharmacol. 2005 Aug;56(2):115-25. doi: 10.1007/s00280-004-0939-2. Epub 2005 Mar 25. Cancer Chemother Pharmacol. 2005. PMID: 15791458
The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells.
Brantley E, Patel V, Stinson SF, Trapani V, Hose CD, Ciolino HP, Yeh GC, Gutkind JS, Sausville EA, Loaiza-PĂ©rez AI. Brantley E, et al. Anticancer Drugs. 2005 Feb;16(2):137-43. doi: 10.1097/00001813-200502000-00004. Anticancer Drugs. 2005. PMID: 15655410
307 results
Jump to page